Active Biotech strengthens patent protection for laquinimod in eye disorders

Active Biotech strengthens patent protection for laquinimod in eye disorders

Active biotechnologies

Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued the decision to grant Active Biotech’s patent relating to the use of laquinimod as a treatment for eye diseases associated with excessive vascularization. The patent will be granted on May 11, 2022, under patent number EP 3886858, and guarantees the protection and market exclusivity of laquinimod in this field of use until 2040. A similar application is pending at the United States Patent Office.

The patent covers the medical use of laquinimod for the treatment of eye-threatening eye disorders such as age-related macular degeneration (wet AMD), corneal neovascularization, choroidal neovascularization, proliferative diabetic retinopathy, retinopathy of prematurity and ischemic retinopathy. .

“We work continuously and diligently with our patent portfolios with the aim of creating comprehensive patent protection around our development programs and in particular optimizing protection in the pathological areas we target with our projects. The now granted European patent for laquinimod further strengthens the protection of laquinimod in devastating eye disorders with high medical need, ”said Helen Tuvesson, CEO.

For more information, please contact:

Helen Tuvesson, CEO+46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO+46 46 19 20 44, hans.kolam@activebiotech.com

This information is information that Active Biotech AB is obliged to disclose under the EU Market Abuse Regulation. This information has been submitted for publication, through the agency of the contact person indicated above, at 08.30 am CET on April 26, 2022.

About laquinimod
Laquinimod is a first-rate immunomodulator that induces immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting the myeloid cell compartment. Laquinimod was developed as a new treatment for inflammatory eye disorders in the first stage of non-infectious uveitis. Laquinimod has been previously studied in patients with neurodegenerative and inflammatory diseases, including a phase III randomized study program in patients with multiple sclerosis (MS). The clinical safety and tolerability of laquinimod are well known and preclinical data in disease models support the use of laquinimod for the treatment of serious eye diseases, including uveitis and ocular disorders with abnormal vascularity.

About active biotechnologies
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that uses its extensive knowledge base and portfolio of compounds to develop world-class immunomodulatory treatments for specialist indications in oncology and immunology with an unmet medical need and significant commercial potential. Following a portfolio refocusing, Active Biotech’s business model aims to advance projects to the clinical development stage and then further develop programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: the fully proprietary immunomodulators of tasquinimod and laquinimod, both with modes of action that include modulating the function of myeloid immune cells, target hematological malignancies and inflammatory disorders of the eye, respectively. Tasquinimod, is in clinical stage Ib / IIa for the treatment of multiple myeloma. Laquinimod is in a Phase I clinical trial with a topical ophthalmic formulation, followed by a Phase II treatment for non-infectious uveitis. Naptumomab, a targeted anticancer immunotherapy, in collaboration with NeoTX Therapeutics, is in a Phase Ib / II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

Active Biotech AB
(Corporate Reg. No. 556223-9227)
Scheelevägen 22, SE-223 63 Lund, Sweden
Tel: +46 (0) 46 19 20 00

Attached

Leave a Comment

Your email address will not be published.